Does Medicaid Cover Belsomra (Suvorexant)? State-by-State Coverage, Prior Authorization, and Appeals

How Belsomra Works and Why Medicaid Classification Matters

Suvorexant blocks both orexin-A and orexin-B receptors in the lateral hypothalamus, reducing the wake-promoting signals that keep insomnia patients alert at night. The FDA approved Belsomra in August 2014 for the treatment of insomnia characterized by difficulty with sleep onset and sleep maintenance [1]. In the two key phase III trials published by Herring et al. in The Lancet Neurology (combined N=3,291), suvorexant 20 mg reduced subjective time to sleep onset by approximately 20 minutes compared to placebo and increased total sleep time by roughly 25 minutes at four weeks [2].

This mechanism differs from older sedative-hypnotics. Benzodiazepine receptor agonists like zolpidem enhance GABAergic inhibition, while suvorexant selectively dampens wakefulness. That pharmacological distinction matters for Medicaid coverage because state formulary committees classify Belsomra as a branded, non-benzodiazepine hypnotic with no AB-rated generic equivalent. The absence of a generic version keeps per-unit costs high. And high cost is the primary reason most state Medicaid programs impose utilization management controls before approving coverage [3].

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline lists suvorexant as a recommended option for sleep maintenance insomnia [4]. That guideline endorsement does not guarantee formulary placement, but it provides the clinical rationale prescribers need when submitting prior authorization requests.

State Medicaid Formulary Placement: What the Data Shows

No two states handle Belsomra identically. Coverage falls into three broad categories.

Some states list suvorexant on their preferred drug list (PDL) with prior authorization. Others place it on a non-preferred tier, meaning coverage is available but requires additional documentation and sometimes a higher copay. A smaller number of states exclude Belsomra from the formulary entirely, requiring an exception request.

States that contract with a single pharmacy benefit manager (PBM) tend to have uniform policies. States that delegate pharmacy benefits to managed care organizations (MCOs) may have different Belsomra policies depending on which MCO a patient is enrolled in. California's Medi-Cal, for example, carves pharmacy benefits into managed care plans, each with its own formulary. New York Medicaid, by contrast, maintains a fee-for-service preferred drug list that MCOs must follow as a floor [5].

As a practical step, patients and prescribers should check the specific formulary for their state and plan. The Centers for Medicare & Medicaid Services (CMS) requires each state Medicaid agency to publish its formulary or PDL publicly [6]. These lists are updated quarterly in most states.

Prior Authorization Criteria Across State Programs

Prior authorization is the most common barrier to Belsomra access under Medicaid. The typical PA form asks for three categories of documentation.

Diagnosis confirmation. The prescriber must document a diagnosis of insomnia disorder, usually with ICD-10 code G47.00 or G47.01. Some states require that insomnia symptoms have persisted for at least three months. A 2019 analysis in JAMA Internal Medicine found that approximately 27.3% of U.S. adults report chronic insomnia symptoms, yet only a fraction receive formal diagnoses documented in claims data [7].

Step therapy documentation. The prescriber must show that the patient tried and failed (or has a contraindication to) at least one first-line generic medication. Zolpidem, trazodone, and doxepin 3-6 mg are the most frequently required step-therapy agents. Some states require failure of two generic agents before approving suvorexant.

Clinical rationale. Many states ask for a brief statement explaining why Belsomra is preferred over remaining generic alternatives. Common acceptable rationales include adverse effects from prior agents, drug interactions (suvorexant avoids the anticholinergic burden of some alternatives), or documented treatment resistance.

PA approvals typically last 6 to 12 months. The Medicaid and CHIP Payment and Access Commission (MACPAC) has noted that PA processing times range from 24 hours to 14 days depending on the state, with federal regulations requiring a decision within 24 hours for urgent requests [8].

Step Therapy Requirements: What You Must Try First

Step therapy protocols for Belsomra follow a predictable pattern. Generic sedative-hypnotics come first. Branded options come last.

The most common step-therapy sequence runs like this: trazodone (off-label, 25-100 mg) or generic zolpidem (5-10 mg) as step one. If step one fails, some states require a trial of generic doxepin 3 mg or 6 mg, which the FDA approved specifically for sleep maintenance insomnia in 2010 [9]. Only after documented failure of these agents will the state authorize suvorexant.

"Failure" definitions vary. Some states accept a prescriber attestation that the patient experienced unacceptable side effects. Others require pharmacy claims data showing at least a 30-day fill of the step-therapy agent. A few states accept documented contraindications (such as a history of complex sleep behaviors with zolpidem, which carries an FDA boxed warning added in 2019) as equivalent to a trial failure [10].

Patients with comorbid substance use disorders may qualify for expedited approval in certain states, since suvorexant is classified as Schedule IV with a lower abuse profile than benzodiazepines. A 2020 post-hoc analysis published in Sleep Medicine found no signal of suvorexant abuse or dependence across 3,291 trial participants followed for up to 12 months [11].

How Much Belsomra Costs Under Medicaid vs. Cash Pay

The financial picture is straightforward. Merck's wholesale acquisition cost (WAC) for Belsomra sits near $340 per month for both the 10 mg and 20 mg strengths [12]. Under Medicaid, the net price after federal and supplemental rebates is substantially lower, but the exact net cost varies by state because of differing supplemental rebate agreements.

Medicaid patients who receive coverage through PA typically pay $0 to $3 per prescription, depending on the state's cost-sharing structure. Federal law caps Medicaid copays at $4 for preferred drugs and $8 for non-preferred drugs for most beneficiaries, with even lower caps for certain populations [6].

For patients whose Medicaid denials are upheld on appeal, cash-pay options exist. GoodRx and similar discount aggregators list suvorexant at approximately $85 per month. The manufacturer, Organon (which acquired the Belsomra brand from Merck in 2021), offers a savings program, but federal anti-kickback statutes prohibit using manufacturer copay cards alongside Medicaid or any other federal healthcare program [13].

That restriction is absolute. Patients enrolled in Medicaid cannot legally use the Belsomra savings card, even if their Medicaid plan denies coverage. The only path is the appeal process or switching to a covered alternative.

How to Appeal a Medicaid Denial of Belsomra

Every state Medicaid program must offer a fair-hearing process. This is a federal requirement under 42 CFR § 431.200 [6]. The steps follow a general pattern, though timelines and procedures differ by state.

Step 1: Internal appeal. After receiving a denial letter, the prescriber or patient files an internal appeal with the MCO or state Medicaid agency. The appeal should include the PA documentation plus any additional clinical notes. Response time is typically 30 days for standard appeals or 72 hours for expedited appeals involving urgent clinical need.

Step 2: External appeal / state fair hearing. If the internal appeal fails, the patient can request a state fair hearing. This is an administrative law proceeding where an impartial hearing officer reviews the case. The patient (or their representative) can present evidence, including letters from the prescribing physician, sleep study results, and documentation of failed alternatives.

Success rates on appeal vary. A 2021 report from the HHS Office of Inspector General found that approximately 18% of prior authorization denials in Medicaid managed care were later overturned on appeal, though the rate for specific drug classes was not broken out [14].

Key tips for a successful appeal: include specific dates and durations of prior medication trials, document objective adverse effects (not just "didn't work"), reference the AASM guideline recommendation for suvorexant [4], and request an expedited hearing if the patient's insomnia is causing safety concerns such as occupational impairment or motor vehicle accident risk.

Suvorexant vs. Lemborexant: Does Medicaid Prefer One DORA Over the Other?

Lemborexant (Dayvigo), the second FDA-approved DORA, received approval in December 2019 [15]. Both drugs target orexin receptors, but they are not interchangeable from a formulary perspective.

Some state Medicaid programs cover one DORA but not the other. A smaller number cover neither without exception. Where both are available, the prior authorization criteria are nearly identical. The choice between them often comes down to which manufacturer has negotiated a larger supplemental rebate with the state.

In clinical trials, lemborexant 5 mg and 10 mg showed comparable efficacy to suvorexant 20 mg on subjective sleep-onset latency and wake-after-sleep-onset measures. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes vs. placebo and 7.6 minutes vs. zolpidem extended-release in adults aged 55 and older [16]. Direct head-to-head trials between the two DORAs do not exist.

If a patient's Medicaid plan covers lemborexant but not suvorexant (or vice versa), switching to the covered agent is often faster than pursuing an appeal. Both carry the same Schedule IV classification and similar side-effect profiles, with next-day somnolence as the most common adverse event.

Who Qualifies for Medicaid Coverage of Belsomra?

Eligibility has two layers. The patient must first qualify for Medicaid itself, and then the prescription must meet the state's clinical criteria for suvorexant.

Medicaid eligibility expanded under the Affordable Care Act in 40 states plus the District of Columbia as of 2026. Adults with household incomes at or below 138% of the federal poverty level ($21,597 for an individual in 2026) qualify in expansion states [6]. Non-expansion states limit adult Medicaid to specific categories such as pregnant women, parents of dependent children, and individuals with disabilities.

Once enrolled, the patient needs a documented insomnia diagnosis and (in most states) evidence of failed generic therapy. Patients with concurrent conditions such as obstructive sleep apnea on CPAP, PTSD-related insomnia, or chronic pain with sleep disruption sometimes receive expedited PA approval because their clinical complexity supports the need for a targeted mechanism like orexin receptor antagonism.

The Endocrine Society and the American Academy of Sleep Medicine both emphasize that insomnia treatment should be individualized, with cognitive behavioral therapy for insomnia (CBT-I) as the first-line intervention and pharmacotherapy reserved for patients who do not respond adequately or who lack access to CBT-I [4]. Documenting a CBT-I trial or referral in the PA request strengthens the case.

Practical Steps to Get Belsomra Covered by Your State Medicaid

Start with your state's Medicaid formulary lookup tool. Most states publish searchable PDLs online. Search for "suvorexant" or "Belsomra" and note the tier, PA requirements, and any quantity limits.

Next, confirm your managed care plan. If your state delegates pharmacy benefits to MCOs, call the number on your Medicaid card and ask specifically: "Is suvorexant on formulary, and what are the prior authorization requirements?" Document the representative's name and the date of the call.

Ask your prescriber to submit the PA proactively. Waiting until the pharmacy rejects the claim adds days to the process. Most electronic health records have built-in ePA (electronic prior authorization) tools that transmit directly to the Medicaid PBM. A 2023 CMS final rule expanded ePA adoption requirements for Medicaid managed care plans, with full implementation required by January 2027 [17].

If denied, file the appeal within the timeframe specified in your denial letter (usually 30 to 60 days). Include a one-page letter from your prescriber stating the diagnosis, prior medication trials with dates, the reason suvorexant is medically necessary, and the AASM guideline reference. Request the hearing in writing and keep a copy of everything submitted.